Prior to founding Aglaia BioMedical Ventures and Aglaia Oncology Fund, Mark Krul held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) in the field of oncology drug development strategies. Before that, Mark Krul was Research Manager of the European Cancer Center and Head of the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection, the Netherlands. Mark initiated in 1989 a European Concerted Action (25 European centers) on “Immunology of HPV and Vaccine Development”, which also was the topic of his Ph.D. thesis. He has a background in molecular biology and immunology and over 20 years of experience in anti-cancer drug development. Mark Krul and his colleagues of Aglaia are founders of ISA Pharmaceuticals.
oncology, drug development